Biotech Company Uses CRISPR to Edit Cholesterol GeneJuly 20, 2022
A patient in New Zealand is the first to undergo DNA editing to lower their blood cholesterol as part of a clinical trial by the U.S. biotechnology company Verve Therapeutics. A version of the gene editing tool CRISPR was injected to modify a single letter of DNA in the patient's liver cells.
Verve Therapeutics said that the tiny edit should be enough to permanently lower a person's levels of “bad” LDL cholesterol, the fatty molecule that causes arteries to clog and harden with time. The gene that Verve is editing is called PCSK9. It has a big role in maintaining LDL levels, and the company says the gene will be turned off by introducing a one-letter misspelling.
The clinical trial in New Zealand will give the gene treatment to 40 people who have an inherited form of high cholesterol known as familial hypercholesterolemia, or FH. People with FH can have twice the average cholesterol readings, even as children. The study also marks the early use of base editing, a CRISPR adaptation first developed in 2016 that substitutes a single letter of DNA for another, unlike traditional CRISPR which cuts a gene.
For more details, read the article in MIT Technology Review.
You might also like:
- First CRISPR Drug Coming Soon
- WHO Releases Framework for Governance of Human Genome Editing
- Chinese Scientists Test CRISPR Gene-editing in Human for the First Time
The Crop Biotech Update is a weekly newsletter of ISAAA, a not-for-profit organization. The CBU is distributed for free to over 23,000 subscribers worldwide to inform them about the key developments in biosciences, especially in agricultural biotechnology. Your support will help us in our mission to feed the world with knowledge. You can help by donating as little as $10.
See more articles:
Research and Tools
- Experts Boost Plant Immunity to Face Warming Temperatures
- Study Gauges Public Acceptance of Gene-edited Foods
- SCNT-CRISPR-Cas9 Combo Successfully Produces Genome-edited Dogs
- Biotech Company Uses CRISPR to Edit Cholesterol Gene
Public Acceptance and Engagement
- High School Teachers Tackle CRISPR in Biotech Classes
- Experts Highlight Gene Editing Potentials for Vietnam’s Agri Sector
Read the latest:
- Crop Biotech Update (August 10, 2022)
- Genome Editing Supplement (August 10, 2022)
- Gene Drive Supplement (July 27, 2022)
Subscribe to CBU: